Cargando…

A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal

BACKGROUND: When designing a randomised controlled trial (RCT), an important consideration is the sample size required. This is calculated from several components; one of which is the target difference. This study aims to review the currently reported methods of elicitation of the target difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothwell, Joanne C., Julious, Steven A., Cooper, Cindy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180439/
https://www.ncbi.nlm.nih.gov/pubmed/30305146
http://dx.doi.org/10.1186/s13063-018-2886-y
_version_ 1783362198779723776
author Rothwell, Joanne C.
Julious, Steven A.
Cooper, Cindy L.
author_facet Rothwell, Joanne C.
Julious, Steven A.
Cooper, Cindy L.
author_sort Rothwell, Joanne C.
collection PubMed
description BACKGROUND: When designing a randomised controlled trial (RCT), an important consideration is the sample size required. This is calculated from several components; one of which is the target difference. This study aims to review the currently reported methods of elicitation of the target difference as well as to quantify the target differences used in Health Technology Assessment (HTA)-funded trials. METHODS: Trials were identified from the National Institute of Health Research Health Technology Assessment journal. A total of 177 RCTs published between 2006 and 2016 were assessed for eligibility. Eligibility was established by the design of the trial and the quality of data available. The trial designs were parallel-group, superiority RCTs with a continuous primary endpoint. Data were extracted and the standardised anticipated and observed effect size estimates were calculated. Exclusion criteria was based on trials not providing enough detail in the sample size calculation and results, and trials not being of parallel-group, superiority design. RESULTS: A total of 107 RCTs were included in the study from 102 reports. The most commonly reported method for effect size derivation was a review of evidence and use of previous research (52.3%). This was common across all clinical areas. The median standardised target effect size was 0.30 (interquartile range: 0.20–0.38), with the median standardised observed effect size 0.11 (IQR 0.05–0.29). The maximum anticipated and observed effect sizes were 0.76 and 1.18, respectively. Only two trials had anticipated target values above 0.60. CONCLUSION: The most commonly reported method of elicitation of the target effect size is previous published research. The average target effect size was 0.3. A clear distinction between the target difference and the minimum clinically important difference is recommended when designing a trial. Transparent explanation of target difference elicitation is advised, with multiple methods including a review of evidence and opinion-seeking advised as the more optimal methods for effect size quantification.
format Online
Article
Text
id pubmed-6180439
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61804392018-10-18 A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal Rothwell, Joanne C. Julious, Steven A. Cooper, Cindy L. Trials Research BACKGROUND: When designing a randomised controlled trial (RCT), an important consideration is the sample size required. This is calculated from several components; one of which is the target difference. This study aims to review the currently reported methods of elicitation of the target difference as well as to quantify the target differences used in Health Technology Assessment (HTA)-funded trials. METHODS: Trials were identified from the National Institute of Health Research Health Technology Assessment journal. A total of 177 RCTs published between 2006 and 2016 were assessed for eligibility. Eligibility was established by the design of the trial and the quality of data available. The trial designs were parallel-group, superiority RCTs with a continuous primary endpoint. Data were extracted and the standardised anticipated and observed effect size estimates were calculated. Exclusion criteria was based on trials not providing enough detail in the sample size calculation and results, and trials not being of parallel-group, superiority design. RESULTS: A total of 107 RCTs were included in the study from 102 reports. The most commonly reported method for effect size derivation was a review of evidence and use of previous research (52.3%). This was common across all clinical areas. The median standardised target effect size was 0.30 (interquartile range: 0.20–0.38), with the median standardised observed effect size 0.11 (IQR 0.05–0.29). The maximum anticipated and observed effect sizes were 0.76 and 1.18, respectively. Only two trials had anticipated target values above 0.60. CONCLUSION: The most commonly reported method of elicitation of the target effect size is previous published research. The average target effect size was 0.3. A clear distinction between the target difference and the minimum clinically important difference is recommended when designing a trial. Transparent explanation of target difference elicitation is advised, with multiple methods including a review of evidence and opinion-seeking advised as the more optimal methods for effect size quantification. BioMed Central 2018-10-10 /pmc/articles/PMC6180439/ /pubmed/30305146 http://dx.doi.org/10.1186/s13063-018-2886-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Rothwell, Joanne C.
Julious, Steven A.
Cooper, Cindy L.
A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal
title A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal
title_full A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal
title_fullStr A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal
title_full_unstemmed A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal
title_short A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal
title_sort study of target effect sizes in randomised controlled trials published in the health technology assessment journal
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180439/
https://www.ncbi.nlm.nih.gov/pubmed/30305146
http://dx.doi.org/10.1186/s13063-018-2886-y
work_keys_str_mv AT rothwelljoannec astudyoftargeteffectsizesinrandomisedcontrolledtrialspublishedinthehealthtechnologyassessmentjournal
AT juliousstevena astudyoftargeteffectsizesinrandomisedcontrolledtrialspublishedinthehealthtechnologyassessmentjournal
AT coopercindyl astudyoftargeteffectsizesinrandomisedcontrolledtrialspublishedinthehealthtechnologyassessmentjournal
AT rothwelljoannec studyoftargeteffectsizesinrandomisedcontrolledtrialspublishedinthehealthtechnologyassessmentjournal
AT juliousstevena studyoftargeteffectsizesinrandomisedcontrolledtrialspublishedinthehealthtechnologyassessmentjournal
AT coopercindyl studyoftargeteffectsizesinrandomisedcontrolledtrialspublishedinthehealthtechnologyassessmentjournal